Xeris Biopharma (XERS) Stock Forecast & Price Target
Score
Xeris Biopharma Holdings, Inc. price target
| XERS | |
|---|---|
| Low | $14.00 |
| Average | $15.00 |
| High | $16.00 |
| Upside vs current price | -10.7% |
The average target of $15.00 is -10.7% versus the current XERS price of $16.80.
Xeris Biopharma Holdings, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 5 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
7 analysts cover XERS.
Xeris Biopharma Holdings, Inc. EPS and revenue estimates
The estimate table for the Xeris Biopharma Holdings, Inc. keeps 2026 EPS $-0.02, 2027 EPS $0.42, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-0.02 | $401.51M |
| 2027 | $0.42 | $526.63M |
Is Xeris Biopharma Holdings, Inc. a buy or sell?
Of the 7 analysts covering Xeris Biopharma Holdings, Inc., 6 rate it a buy (1 strong buy and 5 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The XERS consensus label is Buy, beside 6 buy-side ratings and 0 sell-side ratings.
The average target of $15.00 implies -10.7% versus the current price of $16.80.
the Xeris Biopharma Holdings, Inc. closes with 6 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Xeris Biopharma Holdings, Inc. forecast
There is little daylight between XERS targets. Low $14.00, average $15.00, high $16.00.
From today's $16.80 print, the XERS average target is -10.7% away.
Most of the XERS coverage agrees: 6 of 7 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.
Earnings estimates for XERS are rising: 2026 $-0.02, then 2027 $0.42.
XERS target coverage is thin at 3 firms, and one revision moves the band.
Xeris Biopharma Holdings, Inc. forecast questions
What is the XERS price target?
The published range for XERS is $14.00 to $16.00, with a average target of $15.00. That average is -10.7% versus the current price of $16.80.
Is Xeris Biopharma Holdings, Inc. a buy or sell?
Of the 7 analysts covering Xeris Biopharma Holdings, Inc., 6 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, which for XERS is 6 on the buy side, 1 at hold, and 0 on the sell side.
What is the EPS estimate for Xeris Biopharma Holdings, Inc.?
Analyst EPS estimates for Xeris Biopharma Holdings, Inc.: 2026 $-0.02, 2027 $0.42.
What is the revenue estimate for Xeris Biopharma Holdings, Inc.?
Analyst revenue estimates for Xeris Biopharma Holdings, Inc.: 2026 $401.51M, 2027 $526.63M.
How many analysts cover XERS?
7 analysts cover XERS. Their consensus on XERS is Buy, across those 7.